Positive Results from Interim Analysis of ‘GEN-001’ Plus avelumab (Bavencio®) Phase II Trial
(Adnkronos) – SEOUL, South Korea, May 19, 2023 /PRNewswire/ — Genome & Company (CEO: Pae, Jisoo), a global leading microbiome therapeutics developer, announced that this phase II trial (NCT05419362) will continue without modifications
